Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152386 · ClinicalTrials.gov registry record · Phase 3
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 950
- Enrollment target
NCT00152386 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 950 participants.
The verdict
NCT00152386, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 950 participants
- Enrollment target
Study Summary
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
Interventions
- DRUG Certolizumab pegol (CDP870)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00152386
The ClinicalTrials.gov registry entry for NCT00152386 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 950 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab pegol (CDP870) is the first listed.
NCT00152386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00152386 about?
NCT00152386 is a clinical study titled "A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis". Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
What is the current status of trial NCT00152386?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 950 participants. The study started on 2005-02. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00152386?
The interventions under investigation include: Certolizumab pegol (CDP870) (DRUG).
Who is sponsoring clinical trial NCT00152386?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.